IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct phase I trial of Hondrolux®

October 30, 20017. IPHARMA, a company of ChemRar Group, was authorized by the Ministry of Healthcare of the Russian Federation to conduct phase I trial of Hondrolux®.

Protocol No. OA-CLX-01 “A double-blind, randomized, placebo-controlled trial of the safety and tolerability of increasing doses of Hondrolux® in single and subsequent repeated intramuscular administration in healthy volunteers”.

The clinical trial aim is to evaluate the safety and tolerability profile of Hondrolux® in single and subsequent repeated administration to healthy volunteers, including assessment of tolerability based on the frequency of local reactions.

Area of application: rheumatology.

Hondrolux® was developed by SIA Peptides LLC and is intended for the prevention and treatment of degenerative-dystrophic diseases of the joints and spine.